• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease.

作者信息

Chen Zhiwei, Zhang Yingzhi, Song Rui, Wang Lu, Hu Xiaoxiao, Li Hu, Cai Dachuan, Hu Peng, Shi Xiaofeng, Ren Hong

机构信息

Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Signal Transduct Target Ther. 2022 Jun 2;7(1):174. doi: 10.1038/s41392-022-01032-9.

DOI:10.1038/s41392-022-01032-9
PMID:35654782
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9160847/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c6f/9163049/aaca4685d3e6/41392_2022_1032_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c6f/9163049/aaca4685d3e6/41392_2022_1032_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c6f/9163049/aaca4685d3e6/41392_2022_1032_Fig1_HTML.jpg

相似文献

1
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease.重症肝病患者对新型冠状病毒2型灭活疫苗的体液免疫反应减弱。
Signal Transduct Target Ther. 2022 Jun 2;7(1):174. doi: 10.1038/s41392-022-01032-9.
2
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
3
Weakened humoral immune responses of inactivated SARS-CoV-2 vaccines in patients with solid tumors.实体瘤患者中灭活新型冠状病毒疫苗的体液免疫反应减弱。
Cancer Commun (Lond). 2023 Feb;43(2):280-284. doi: 10.1002/cac2.12368. Epub 2022 Nov 4.
4
A three-dose inactivated SARS-CoV-2 vaccine is sufficient to elicit humoral immune responses in people living with HIV-1.三剂灭活严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗足以在感染人类免疫缺陷病毒1型（HIV-1）的人群中引发体液免疫反应。
Chin Med J (Engl). 2023 Sep 20;136(18):2243-2245. doi: 10.1097/CM9.0000000000002810. Epub 2023 Aug 17.
5
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.接种 COVID-19 mRNA 疫苗后，需要数天才能诱导针对 SARS-CoV-2 的高特异性体液和细胞反应。
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
6
Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.上呼吸道的固有和适应性免疫反应与 SARS-CoV-2 的传染性。
Viruses. 2022 Apr 29;14(5):933. doi: 10.3390/v14050933.
7
Getting to the (germinal) center of humoral immune responses to SARS-CoV-2.深入探究体液免疫应答 SARS-CoV-2 的（生发）中心。
Cell. 2022 Mar 17;185(6):945-948. doi: 10.1016/j.cell.2022.02.018.
8
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.接受B细胞清除疗法的抗中性粒细胞胞浆抗体相关性血管炎患者接种新型冠状病毒疫苗后的抗原特异性体液免疫和细胞免疫
Front Immunol. 2022 Jan 28;13:834981. doi: 10.3389/fimmu.2022.834981. eCollection 2022.
9
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA 新冠病毒疫苗接种后长期血液透析患者中产生强烈细胞和体液免疫应答。
Front Immunol. 2022 Mar 23;13:845882. doi: 10.3389/fimmu.2022.845882. eCollection 2022.
10
Blunted humoral response after mRNA vaccine in patients with haematological malignancies.血液系统恶性肿瘤患者接种mRNA疫苗后体液免疫反应减弱。
Lancet Haematol. 2021 Aug;8(8):e540-e542. doi: 10.1016/S2352-3026(21)00197-6. Epub 2021 Jul 2.

引用本文的文献

1
Distinct features of humoral and cellular immunity against Omicron breakthrough infection among chronic liver disease patients: An experience from a follow-up cohort.慢性肝病患者中针对奥密克戎突破性感染的体液免疫和细胞免疫的独特特征：一项随访队列研究经验
Hum Vaccin Immunother. 2025 Dec;21(1):2544466. doi: 10.1080/21645515.2025.2544466. Epub 2025 Aug 15.
2
Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis.新型冠状病毒疫苗在慢性肝病患者中的安全性和有效性：一项系统评价与荟萃分析
Int J Public Health. 2024 Nov 21;69:1605295. doi: 10.3389/ijph.2024.1605295. eCollection 2024.
3

本文引用的文献

1
Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection.一种新型冠状病毒2型灭活疫苗在慢性乙型肝炎病毒感染患者中的安全性和免疫原性。
Cell Mol Immunol. 2021 Dec;18(12):2679-2681. doi: 10.1038/s41423-021-00795-5. Epub 2021 Nov 15.
2
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.非酒精性脂肪性肝病患者 COVID-19 疫苗接种的安全性和免疫原性（CHESS2101）：一项多中心研究。
J Hepatol. 2021 Aug;75(2):439-441. doi: 10.1016/j.jhep.2021.04.026. Epub 2021 Apr 24.
3
Durable SARS-CoV-2 B cell immunity after mild or severe disease.
Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.
代谢功能障碍相关脂肪性肝病对BNT162b2针对严重急性呼吸综合征冠状病毒2奥密克戎变种免疫原性的影响。
J Gastroenterol Hepatol. 2024 Nov;39(11):2386-2393. doi: 10.1111/jgh.16716. Epub 2024 Aug 17.
4
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.新冠病毒疫苗在肝硬化患者中的免疫原性：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2326316. doi: 10.1080/21645515.2024.2326316. Epub 2024 Mar 11.
5
Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.自身免疫性肝病患者初次和加强接种灭活新冠病毒疫苗后的安全性和免疫原性
J Clin Transl Hepatol. 2024 Feb 28;12(2):162-171. doi: 10.14218/JCTH.2023.00049. Epub 2023 Sep 6.
6
Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis.肝硬化患者对初次和加强免疫接种灭活新型冠状病毒疫苗的动态体液免疫反应
J Clin Transl Hepatol. 2023 Dec 28;11(7):1476-1484. doi: 10.14218/JCTH.2023.00108. Epub 2023 Aug 25.
7
Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.灭活的 SARS-CoV-2 加强疫苗增强了慢性肝病患者的免疫应答。
Virol Sin. 2023 Oct;38(5):723-734. doi: 10.1016/j.virs.2023.07.005. Epub 2023 Jul 22.
8
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.COVID-19 对有和无预先存在的消化系统疾病的个体的影响，特别关注老年患者。
World J Gastroenterol. 2023 Jul 14;29(26):4099-4119. doi: 10.3748/wjg.v29.i26.4099.
9
Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review.抗SARS-CoV-2疫苗在肝硬化患者中的疗效、安全性和免疫原性：一项叙述性综述。
Vaccines (Basel). 2023 Feb 16;11(2):452. doi: 10.3390/vaccines11020452.
10
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease.肝硬化与慢性肝病患者对新冠疫苗的血清学反应较低有关。
JHEP Rep. 2023 May;5(5):100697. doi: 10.1016/j.jhepr.2023.100697. Epub 2023 Feb 20.
轻度或重度疾病后 SARS-CoV-2 持久的 B 细胞免疫。
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI145516.
4
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.EASL 立场文件：关于在慢性肝病、肝胆癌和肝移植受者中使用 COVID-19 疫苗的建议。
J Hepatol. 2021 Apr;74(4):944-951. doi: 10.1016/j.jhep.2021.01.032. Epub 2021 Feb 6.
5
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.